Table 5: Hemostatic markers unaffected by warfarin in NVAF patients with a history of an embolic event and control subjects with a history of thrombotic stroke
Variable	Group; mean value (and SD)		Difference in means (and 95% CI)	Adjusted p value*
	NVAF patients with history of event n = 25	Control subjects with history of stroke n = 11
Hemoglobin, g/L	141  (12)	143  (17)	-2  (-13, 9)	0.48
Platelet count, × 109/L	253  (82)	242  (77)	11  (-45, 66)	0.94
Fibrinogen, g/L	3.8  (0.9)	4.0  (0.9)	-0.2  (-0.8, 0.4)	0.28
Von Willebrand factor antigen, µ/mL	2.1  (0.6)	2.3  (1.2)	-0.2  (-0.9, 0.5)	0.12
Factor VIII, µ/mL	1.6  (0.5)	1.7  (0.7)	-0.1  (-0.6, 0.4)	0.08
Fibrin D­dimer, % of subjects with level < 200, 200-500 and > 500 ng/mL respectively	92, 4, 4	94, 4, 2	--
Antithrombin III, µ/mL	1.00  (0.14)	1.00  (0.13)	0  (-0.09, 0.09)	0.74
*Determined by ANOVA, for difference between groups after adjustment for age and sex.

[Return to text]